How effective is venetoclax/venetoclax? New hope for leukemia patients

Venetoclax is an oral BCL-2 inhibitor that has shown remarkable efficacy in the treatment of leukemia in recent years, especially in patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). BCL-2 is an anti-apoptotic protein that helps cancer cells escape the normal cell death process. By specifically inhibiting the BCL-2 protein, venetoclax promotes programmed death (apoptosis) of leukemia cells, thereby slowing or preventing the progression of cancer.

In the treatment of chronic lymphocytic leukemia (CLL), the combination of venetoclax and the anti-CD20 monoclonal antibody drug (such as alemtuzumab) produced by the Swiss pharmaceutical company Roche has shown significant results, especially for patients who have received multiple treatments but still relapsed. Clinical trial results show that venetoclax can significantly extend the progression-free survival (PFS) and overall survival (OS) of these patients. For patients with acute myeloid leukemia (AML), the combination of venetoclax and chemotherapy drugs can improve the therapeutic effect, especially in elderly patients and patients who cannot tolerate traditional chemotherapy.

The efficacy of venetoclax in clinical application is not only reflected in improving patients' symptoms, but also by reducing the chance of disease recurrence, becoming a new hope for the treatment of leukemia. It has been approved by many countries for the treatment of various types of leukemia, especially CLL and AML. In multiple clinical studies, venetoclax has demonstrated strong anti-tumor activity and good safety. For those patients for whom traditional treatments are ineffective, Venetoclax undoubtedly brings new treatment options.

However, the efficacy of venetoclax is not without challenges. Although it can significantly improve the survival status of most patients, the occurrence of drug resistance is still a major problem in its clinical application. As treatment progresses, some patients may develop resistance to the drug, resulting in reduced therapeutic efficacy. Therefore, how to further improve the efficacy of venetoclax and delay the occurrence of drug resistance is still the focus of current research.

Reference materials:https://www.venclexta.com/